Status:
COMPLETED
Faslodex Post Marketing Surveillance
Lead Sponsor:
AstraZeneca
Conditions:
Breast Cancer
Eligibility:
FEMALE
Brief Summary
This PMS aims to assess the efficacy, the safety and tolerability profile of Faslodex in everyday practice. Secondary objective of this PMS is to identify the frequency of serious adverse events or an...
Eligibility Criteria
Inclusion
- Postmenopausal women
- Patients who have failed 2 or more prior hormone therapies (The prior hormone therapies should contain both antiestrogen and non-steroidal Aromatase inhibitor)
- Patients who were intolerant to prior hormone therapy and have no endocrine therapeutic options (The prior hormone therapies should contain both antiestrogen and non-steroidal Aromatase inhibitor)
Exclusion
- The patients who received Faslodex treatment before
Key Trial Info
Start Date :
January 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2013
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00860561
Start Date
January 1 2009
End Date
October 1 2013
Last Update
October 10 2014
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Cheonan, South Korea
2
Research Site
Daegu, South Korea
3
Research Site
Daejeon, South Korea
4
Research Site
Iksan, South Korea